TumorDiagnostik & Therapie 2007; 28(3): 129-132
DOI: 10.1055/s-2007-963252
Thieme Onkologie aktuell

© Georg Thieme Verlag KG Stuttgart · New York

Gentherapeutische Strategien gegen das kolorektale Karzinom

Gene therapy approaches for colorectal cancerA. Mohr1 , M. Lyons1 , W. Mohr1 , R. M. Zwacka1, 2
  • 1National Centre for Biomedical Engineering Science, National University of Ireland, Galway
  • 2Universitätsklinikum Ulm, Sektion Gentherapie, Universität Ulm
Further Information

Publication History

eingereicht: 19.10.2006

angenommen: 8.2.2007

Publication Date:
15 June 2007 (online)

Literatur

  • 1 Weitz J, Koch M, Debus J, Hohler T, Galle P R, Buchler M W. Colorectal cancer.  Lancet. 2005;  365 153-365
  • 2 Venook A. Critical evaluation of current treatments in metastatic colorectal cancer.  Oncologist. 2005;  10 250-261
  • 3 Zwacka R M, Dunlop M G. Gene therapy for colon cancer.  Hematol Oncol Clin North Am. 1998;  12 595-615
  • 4 Cross D, Burmester J K. Gene therapy for cancer treatment: past, present and future.  Clin Med Res. 2006;  4 218-227
  • 5 Bischoff J R, Kirn D H, Williams A. et al . An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.  Science. 1996;  274 373-376
  • 6 Li C, Bowles D E, Dyke van T, Samulski R J. Adeno-associated virus vectors: potential applications for cancer gene therapy.  Cancer Gene Ther. 2005;  12 913-925
  • 7 Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin K M, Weiher H, Fisher K J, Zwacka R M. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.  Gene Ther. 2004;  11 534-543
  • 8 Glick R P, Lichtor T, Cohen E P. Cytokine immunogene therapy.  Neurosurg Focus. 2000;  9 e2
  • 9 Morgan R A, Dudley M E, Wunderlich J R. et al . Cancer regression in patients after transfer of genetically engineered lymphocytes.  Science. 2006;  314 126-129
  • 10 Studeny M, Marini F C, Champlin R E, Zompetta C, Fidler I J, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.  Cancer Res. 2002;  62 3603-3608

Dr. Ralf Zwacka

Universität Ulm
Sektion Gentherapie

Helmholtzstraße 8/1

89081 Ulm

Phone: ++ 49-731-500 33617

Fax: ++ 49-731-500 33609

Email: ralf.zwacka@uni-ulm.de